Published online Feb 24, 2020. doi: 10.5306/wjco.v11.i2.74
Peer-review started: March 20, 2019
First decision: May 7, 2019
Revised: August 25, 2019
Accepted: December 6, 2019
Article in press: December 6, 2019
Published online: February 24, 2020
Processing time: 307 Days and 19 Hours
Currently, there is no clear consensus on the best imaging modality or follow-up duration for patients with primary extremity soft tissue sarcoma (eSTS), which is important to detect metastases to unusual sites, including the abdomen and retroperitoneum.
There is limited knowledge on incidence, treatment and outcome of abdominal metastases (AM) and retroperitoneal metastases (RM) in patients with primary eSTS undergoing surgery with curative intent.
The objective of the present systematic review was to summarise current knowledge on incidence, diagnosis, treatment and outcome of AM and RM in eSTS patients.
A systematic literature review was performed, screening all studies published in PubMed between January, 2000 and December, 2018 adhering to the PRISMA guidelines. Of 899 articles screened, 17 were eligible to be included in the present review.
Six original articles of the 17 studies provided information on incidence ± diagnosis, therapy and outcome, whilst three original articles and eight case reports did not allow for conclusions on the incidence of AM/RM. Incidence of AM/RM ranged between 0.9%-12.1%, depending on the underlying histological subtype. (Myxoid) liposarcoma and leiomyosarcoma were the prevalent histological subtypes, although rare entities had also been reported to develop AM/RM. Surgery was performed in 62.5% of case reports and in 20.8%-100.0% of original articles, with patients undergoing metastasectomy having an improved outcome. Especially in patients with hepatic metastases, metastasectomy was associated with improved post-metastasis survival.
Abdominal ultrasonography/ computed tomography (CT) should be performed on a regular basis during follow-up in eSTS patients. In patients with a high risk of developing AM/RM– especially those with myxoid liposarcoma – even whole-body magnetic resonance imaging may be considered.
Prospective studies investigating the effect of surveillance with abdominal ultrasonography or CT scans of the abdomen for reporting incidences of AM/RM as well as patient outcome are warranted.